Myocardial Damage in COVID-19

Huazhong University of Science and Technology

Status: Unknown

Conditions: COVID-19; Cardiovascular Diseases

Treatments: Other: non

Study type: Observational

Funder types: Other

Identifiers

NCT04312464

MD-COVID-19

Details and patient eligibility

About

This study aims to investigate the clinical characteristics, the incidence of myocardial injury, and the influence of myocardial injury on the prognosis in COVID-19 patients. There is no additional examination and treatment for this project.

Full description

The epidemic of the COVID-19 has expanded from Wuhan through out China, and is being exported to a growing number of countries. Recently, investigators have revealed that acute myocardial injury is existed in 7.2% patients with COVID-19, and this proportion in patients admitted to the ICU (22.2%) is higher than patients not treated in the ICU (2.0%). Thus, cardiac troponin I (cTNI), the biomarker of cardiac injury, might be a clinical predictor of COVID-19 patient outcomes. This study aims to investigate the clinical characteristics, the incidence of myocardial injury, and the influence of myocardial injury on the prognosis in COVID-19 patients.

Enrollment: 500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• (1) Age ≥18 years. (2) Laboratory (RT-PCR) confirmed infection with SARS-CoV-2. (3) Lung involvement confirmed with chest imaging.

Exclusion criteria

• No cTnI test on admission

Trial design

500 participants in 2 patient groups

Discharged group

Description:

The individual which is defined as patient discharged from hospital

Treatment:

Other: non

Dead group

Description:

The individual which is defined as patient with all-cause death

Treatment:

Other: non